Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 3/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 3/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286452 | 0.82 | PIN1 (0.52) | MPOPIN1DHFRDCPSKDM4E | |
| SCHEMBL28939350 | 0.78 | MGMT (0.33) | PIN1MGMTDHFRCSF1RCDK1 | |
| SCHEMBL23022157 | 0.77 | HTT (0.32) | PIN1MGMTCSF1RCDK1CCNB1 | |
| SCHEMBL23012125 | 0.76 | MGMT (0.51) | PIN1MGMTCDK1CCNB1CCNA2 | |
| SCHEMBL29507214 | 0.75 | MGMT (0.53) | MGMTKDM4E | |
| SCHEMBL23022096 | 0.75 | MGMT (0.53) | MGMTKDM4E | |
| SCHEMBL557629 | 0.74 | MGMT (0.50) | MPOPIN1MGMTDHFRDCPS | |
| SCHEMBL29364376 | 0.74 | MGMT (0.50) | MPOPIN1MGMTDHFRDCPS | |
| SCHEMBL23022067 | 0.72 | NOS1 (0.44) | MPOMGMTKDM4ECSF1R | |
| SCHEMBL488752 | 0.71 | CSF1R (0.57) | MPOCCR4KDM4ECSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | MPO 2476/4885PIN1 2755/4885MGMT 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.